ModerateGlucocorticoids×Vitamin K antagonist anticoagulants
Updated · Methodology
Mechanism
Dexamethasone is a weak CYP3A4 inducer and a potential weak CYP2C9 inhibitor. Effect on INR is unpredictable and usually mild: INR may fall in some patients and rise in others.
Symptoms
Gum bleeding, epistaxis, bruising without trauma, black or tarry stools, haematuria. Higher risk in older patients, prior peptic ulcer disease, and chronic kidney disease.
Management
For short dexamethasone courses (3–5 days), no special monitoring needed. For longer therapy, check INR at one week, then every 2 weeks. Beyond the INR effect, glucocorticoids add gastrointestinal bleeding risk via mucosal ulcerogenic action.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- FDA: Warfarin sodium tablet (Amneal Pharmaceuticals LLC) – Prescribing Information (2017)– ; DailyMed setid 558b7a0d-5490-4c1b-802e-3ab3f1efe760
- AEMPS: Ficha técnica: Dexametasona (nº registro 86123), sección 4.5 (2026)– AEMPS, CIMA, nº registro 86123, revisión 05/2026, sección 4.5